When does liraglutide’s patent expire in Japan?
The exact Japan expiry date depends on which right you mean (the original compound patent, method-of-use patents, or supplemental patent terms) because different claims can expire on different dates. Public sources provided here do not include the specific Japan patent filing details or term calculations needed to state a single, definitive expiry date.
How do you find the correct Japan expiry date (compound vs. use vs. formulation)?
To determine “the” expiry date for liraglutide in Japan, you typically need to identify the specific Japanese patents covering:
- the liraglutide active ingredient (compound) and claim scope,
- specific dosing schedules or indications (method-of-use),
- manufacturing/formulation improvements (if any),
- and whether any term extensions apply under Japanese rules.
Those different layers can create multiple expiry milestones, which matter for when generic or biosimilar products can enter the market.
Does Japan use the same concept as “Bolar”/regulatory-related timing for generics?
Japan’s approval pathway timing for generic medicines and biosimilars can be affected by patent status, regulatory exclusivity concepts, and litigation. Even if a patent term ends, market entry may still be constrained if other patents covering use/indications are still active.
Are there multiple liraglutide patents still blocking entry after the main one ends?
Yes. For medicines like liraglutide, it’s common to see overlapping patent families (compound plus additional patents on use, combinations, or technical improvements). That can mean that one patent expiry does not fully clear the way for competition in every marketed indication.
What sources can give the real Japan expiry date for your specific situation?
The most reliable way to get the exact expiry date for Japan is to check:
- the Japanese patent record for the liraglutide patent family tied to the marketed product(s),
- Japan’s IP status/coverage lists (where available) for the relevant brand and indication,
- and, if applicable, any known patent disputes that affect enforceability.
Quick clarifying question (so the date can be pinned down)
Which Japan product/indication do you mean?
- Victoza (liraglutide) for diabetes (dose differs by region), or
- Saxenda (liraglutide) for weight management, and/or
- a specific combination or dosing regimen.
If you tell me the product name you care about (and ideally the company/brand in Japan), I can narrow the “right” patent family you’re asking about and give the correct expiry date framework for that case.
Sources
No external sources were provided in the prompt, so I cannot cite specific Japan patent expiry dates here.